Lipocine Past Earnings Performance
Past criteria checks 0/6
Lipocine has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 66.5% per year.
Key information
18.2%
Earnings growth rate
43.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 66.5% |
| Return on equity | -34.9% |
| Net Margin | -2,007.5% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lipocine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 1 | -11 | 4 | 10 |
| 31 Dec 22 | 1 | -11 | 4 | 9 |
| 30 Sep 22 | 17 | 4 | 4 | 9 |
| 30 Jun 22 | 17 | 3 | 5 | 9 |
| 31 Mar 22 | 16 | -1 | 5 | 8 |
| 31 Dec 21 | 16 | -1 | 5 | 8 |
| 30 Sep 21 | 0 | -18 | 7 | 8 |
| 30 Jun 21 | 0 | -19 | 7 | 8 |
| 31 Mar 21 | 0 | -19 | 8 | 9 |
| 31 Dec 20 | 0 | -21 | 8 | 10 |
| 30 Sep 20 | 0 | -20 | 8 | 9 |
| 30 Jun 20 | 0 | -18 | 7 | 8 |
| 31 Mar 20 | 0 | -16 | 7 | 8 |
| 31 Dec 19 | 0 | -13 | 6 | 7 |
| 30 Sep 19 | 0 | -13 | 5 | 8 |
| 30 Jun 19 | 0 | -12 | 4 | 8 |
| 31 Mar 19 | 0 | -12 | 5 | 7 |
| 31 Dec 18 | 0 | -12 | 5 | 6 |
| 30 Sep 18 | 0 | -14 | 8 | 6 |
| 30 Jun 18 | 0 | -16 | 10 | 7 |
| 31 Mar 18 | 0 | -19 | 10 | 12 |
| 31 Dec 17 | 0 | -21 | 10 | 11 |
| 30 Sep 17 | 0 | -19 | 8 | 11 |
| 30 Jun 17 | 0 | -17 | 7 | 10 |
| 31 Mar 17 | 0 | -17 | 8 | 6 |
| 31 Dec 16 | 0 | -19 | 10 | 8 |
| 30 Sep 16 | 0 | -21 | 11 | 7 |
| 30 Jun 16 | 0 | -24 | 11 | 10 |
| 31 Mar 16 | 0 | -22 | 9 | 11 |
| 31 Dec 15 | 0 | -18 | 6 | 13 |
| 30 Sep 15 | 0 | -18 | 5 | 13 |
| 30 Jun 15 | 0 | -15 | 4 | 11 |
| 31 Mar 15 | 0 | -18 | 4 | 14 |
| 31 Dec 14 | 0 | -20 | 5 | 15 |
| 30 Sep 14 | 0 | -21 | 5 | 18 |
| 30 Jun 14 | 0 | -20 | 5 | 14 |
| 31 Mar 14 | 0 | -15 | 5 | 8 |
| 31 Dec 13 | 0 | -11 | 4 | 5 |
| 30 Sep 13 | 0 | -7 | 3 | -1 |
| 30 Jun 13 | 0 | -4 | 2 | -1 |
| 31 Mar 13 | 0 | -4 | 2 | 0 |
| 31 Dec 12 | 8 | 4 | 2 | 0 |
Quality Earnings: 2VT0 is currently unprofitable.
Growing Profit Margin: 2VT0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2VT0 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare 2VT0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2VT0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 2VT0 has a negative Return on Equity (-34.86%), as it is currently unprofitable.